Vision

Vision

Achelios_Vision

  • Achelios is in a unique position to provide a marketplace solution to an ongoing unmet medical need: the use of topical medications for the treatment of pain and inflammation.
  • Achelios’ proprietary drug delivery technology, ACHETOGEL™, has been able to deliver significant quantities of active ingredient through the dermis to the underlying target tissue. Clinical proof-of-concept for this technology was achieved during the development of the company’s lead product, TOPOFEN™ (ketoprofen), for the indication of acute migraine.
  • The Company intends to pursue the additional indications of prophylactic migraine, osteoarthritis, sprains and strains, and TMJ using the TOPOFEN™ asset.
  • Given the similar mechanism-of-action found in NSAIDs, Achelios will also pursue the development of other topical NSAID formulations for the indications of osteoarthritis and sprains and strains.
  • It is the Company’s goal to take a major role in the field of transdermal pain treatments, and it believes it is well positioned to do so via the TOPOGEL™ platform.